



PROGRESS TOWARDS AN HIV VACCINE

We have made **tremendous progress** in the treatment and prevention of HIV

...but HIV remains one of the **greatest global health challenges** of our time


HIV affects **37 million** people around the world¹


1.8 million new cases every year¹


J&J and its partners are evaluating **novel vaccine concepts** for HIV


Together our hope is to **make HIV history**

“ Developing a vaccine against HIV is a top priority and our best hope for a world without AIDS. Finding an effective HIV vaccine to protect people at risk has been a major scientific challenge, but today there is new optimism that we can get there. ”

Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson

THE ULTIMATE GOAL

We are innovating to help patients currently facing a lifetime of treatment.

We are investigating strategies to achieve remission.

And our ultimate goal is to find a preventive vaccine for HIV, because experts agree that this is needed to turn the tide of the HIV pandemic.


We are evaluating innovative "mosaic-based" vaccine candidates, which are designed to work as "global vaccines" potentially capable of preventing a wide range of viral strains responsible for the HIV pandemic.

Viral vectors are combined with soluble proteins to form mosaic-based heterologous prime-boost vaccine regimens which first prime and then boost the immune system.

Mosaic vaccines are delivered through viral vectors based on our unique AdVac[®] and PER.C6[®] technology. PER.C6 is also the manufacturing platform for the HIV envelope proteins used in the boost vaccinations.

With our partners, we have initiated the first efficacy study for a mosaic-based investigational HIV-1 preventive vaccine. The study will evaluate whether a lead vaccine regimen comprising the 4-component Ad26 mosaic candidate and a Clade C gp140 soluble protein is able to reduce the incidence of HIV infection among women in sub-Saharan Africa.

Johnson & Johnson is bringing together:



AdVac[®]/PER.C6[®]
technology



Expert
teams



Global research and
funding partners



Manufacturing
capabilities